Martínez-Amorós Erika, Serra Pilar, Goldberg Ximena, Urraca Lara, Palao Diego J, Urretavizcaya Mikel, Cardoner Narcís
Departamento de Salud Mental, Hospital Universitario Parc Taulí de Sabadell, Institut d'Investigació i Innovació Sanitària Parc Taulí (I3PT), Departamento de Psiquiatría y Medicina Legal, Universitat Autònoma de Barcelona, Barcelona, España; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, España.
Departamento de Salud Mental, Hospital Universitario Parc Taulí de Sabadell, Institut d'Investigació i Innovació Sanitària Parc Taulí (I3PT), Departamento de Psiquiatría y Medicina Legal, Universitat Autònoma de Barcelona, Barcelona, España.
Rev Psiquiatr Salud Ment (Engl Ed). 2020 Jan-Mar;13(1):5-10. doi: 10.1016/j.rpsm.2019.07.001. Epub 2019 Aug 29.
Continuation and maintenance electroconvulsive therapy (c/m-ECT) is a therapeutic option after an acute ECT course. Although it is widely used, both duration and the outcome of patients when ECT-c/m is discontinued is not yet well established. The aim of the study was to evaluate the recurrence rate and associated clinical factors when c/m-ECT is discontinued.
Retrospective evaluation of 73 patients who were discontinued from c/m-ECT. The minimum evaluation time was one year. The need of hospital admission or a new acute course of ECT was considered a relapse. The recurrence rate was calculated as a percentage and the estimated time to recurrence was analyzed through a survival analysis. Possible associations between clinical variables and recurrence were analyzed by univariate and multivariate Cox analysis.
Thirty-six patients (49.3%) relapsed: 61.1% of them relapsed during the first year after the c/m-ECT discontinuation (36.1% during the first 6 months). The estimated time to recurrence was 38.67 months. Fifty percent of patients who relapsed required a new acute course of ECT and 44.4% of them restarted c/m-ECT. Patients with an interval between sessions of less than one month and those with more previous episodes showed a higher risk of recurrence.
The risk of recurrence should be considered before the discontinuation of c/m-ECT. After the discontinuation, almost half of the patients relapsed, most of them within the first year. Close monitoring should be conducted in these patients and the discontinuation is not recommended when it is administered at intervals between sessions of less than a month. Further studies are required to identify risk groups for relapse.
延续性和维持性电休克治疗(c/m-ECT)是急性电休克治疗疗程后的一种治疗选择。尽管其应用广泛,但电休克延续性/维持性治疗中断时的疗程时长及患者预后尚未完全明确。本研究旨在评估c/m-ECT中断后的复发率及相关临床因素。
对73例中断c/m-ECT治疗的患者进行回顾性评估。最短评估时间为1年。需住院或进行新的急性电休克治疗疗程被视为复发。复发率以百分比计算,并通过生存分析来分析复发的估计时间。通过单因素和多因素Cox分析来分析临床变量与复发之间可能存在的关联。
36例患者(49.3%)复发:其中61.1%在c/m-ECT中断后的第1年内复发(前6个月内复发率为36.1%)。复发的估计时间为38.67个月。复发患者中有50%需要进行新的急性电休克治疗疗程,其中44.4%重新开始c/m-ECT治疗。治疗间隔时间少于1个月的患者以及既往发作次数较多的患者复发风险更高。
在中断c/m-ECT治疗前应考虑复发风险。中断治疗后,近一半的患者复发,大多数在第1年内复发。应对这些患者进行密切监测,当治疗间隔时间少于1个月时不建议中断治疗。需要进一步研究以确定复发的风险群体。